|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Fasenra
|
|
gptkbp:activities
|
depletes eosinophils
|
|
gptkbp:appointed_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2017
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Fasenra
|
|
gptkbp:clinical_trial
|
gptkb:SIROCCO
Phase III
BORA
long-term management
CALIMA
ZONDA
|
|
gptkbp:contraindication
|
active infections
hypersensitivity to benralizumab
|
|
gptkbp:developed_by
|
gptkb:temple
|
|
gptkbp:dosage_form
|
gptkb:software_framework
|
|
gptkbp:effective_date
|
gptkb:2017
|
|
gptkbp:frequency
|
every 8 weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
benralizumab
|
|
gptkbp:indication
|
severe asthma
hypereosinophilia
chronic rhinosinusitis
|
|
gptkbp:ingredients
|
C646 H1008 N174 O202 S4
|
|
gptkbp:interacts_with
|
none known
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_monitored_by
|
respiratory function
eosinophil counts
|
|
gptkbp:is_used_for
|
gptkb:asthma
eosinophilic esophagitis
|
|
gptkbp:lifespan
|
15 days
|
|
gptkbp:manager
|
subcutaneous
|
|
gptkbp:market
|
gptkb:2018
|
|
gptkbp:marketed_as
|
gptkb:Fasenra
|
|
gptkbp:pharmacokinetics
|
linear pharmacokinetics
IL-5 inhibition
|
|
gptkbp:population
|
gptkb:Person
adults
|
|
gptkbp:provides_information_on
|
NICE guidelines
GINA guidelines
|
|
gptkbp:receives_funding_from
|
public and private sectors
|
|
gptkbp:research_areas
|
asthma treatment
eosinophilic disorders
|
|
gptkbp:rounds
|
metabolism
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:sales
|
increasing
|
|
gptkbp:side_effect
|
headache
fever
urticaria
injection site reactions
anaphylaxis
thrombocytopenia
angioedema
serious infections
pharyngitis
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
gptkb:IL-5_receptor
|
|
gptkbp:treatment
|
improved quality of life
improved asthma control
reduced exacerbations
|
|
gptkbp:weight
|
146 k Da
|